Direct vascular effects of HMG-CoA reductase inhibitors

被引:192
作者
Bellosta, S
Bernini, F
Ferri, N
Quarato, P
Canavesi, M
Arnaboldi, L
Fumagalli, R
Paoletti, R
Corsini, A
机构
[1] Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy
[2] Univ Parma, Inst Pharmacol & Pharmacognosy, I-43100 Parma, Italy
关键词
statins; SMC proliferation; macrophages; AcLDL; isoprenoids;
D O I
10.1016/S0021-9150(97)00319-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several studies have demonstrated that any beneficial effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events are linked to their hypocholesterolemic properties. However, since mevalonic acid (MVA), the product of the enzyme reaction, is the precursor of numerous metabolites, inhibition of HMG-CoA reductase has the potential to result in pleiotropic effects. MVA and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions, hence effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently, we provided in vitro evidence that fluvastatin, simvastatin, lovastatin, cerivastatin, but not pravastatin, dose-dependently decrease smooth muscle cells (SMC) migration and proliferation, independently of their ability to reduce plasma cholesterol. Moreover, statins are able to reduce the in vitro cholesterol accumulation in macrophages, by blocking cholesterol esterification and endocytosis of modified lipoproteins. This in vitro inhibition was completely prevented by the addition of mevalonate and partially by all-trans farnesol and all-trans geranylgeraniol, confirming the specific role of isoprenoid metabolites-probably through a prenylated protein(s)-in regulating these cellular events. The inhibitory effect of lipophilic statins on SMC proliferation has been recently shown in different models of proliferating cells such as cultured arterial myocytes and rapidly proliferating carotid and femoral intimal lesions in rabbits. Finally, ex vivo studies recently showed that sera from fluvastatin-treated patients interfere with smooth muscle cell proliferation. These results suggest that HMG-CoA reductase inhibitors exert a direct antiatherosclerotic effect in the arterial wall, beyond their effects on plasma lipids, that could translate into a more significant prevention of cardiovascular disease. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S101 / S109
页数:9
相关论文
共 66 条
  • [1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT
    ALBERTS, AW
    CHEN, J
    KURON, G
    HUNT, V
    HUFF, J
    HOFFMAN, C
    ROTHROCK, J
    LOPEZ, M
    JOSHUA, H
    HARRIS, E
    PATCHETT, A
    MONAGHAN, R
    CURRIE, S
    STAPLEY, E
    ALBERSSCHONBERG, G
    HENSENS, O
    HIRSHFIELD, J
    HOOGSTEEN, K
    LIESCH, J
    SPRINGER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07): : 3957 - 3961
  • [2] [Anonymous], 1994, CIRCULATION
  • [3] Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
    BakkerArkema, RG
    Davidson, MH
    Goldstein, RJ
    Davignon, J
    Isaacsohn, JL
    Weiss, SR
    Keilson, LM
    Brown, WV
    Miller, VT
    Shurzinske, LJ
    Black, DM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02): : 128 - 133
  • [4] Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery
    Bandoh, T
    Mitani, H
    Niihashi, M
    Kusumi, Y
    Ishikawa, J
    Kimura, M
    Totsuka, T
    Sakurai, I
    Hayashi, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (01) : 37 - 42
  • [5] BELLOSTA S, 1997, UNPUT ATHEROSCLEROSI, V134, P228
  • [6] REQUIREMENT FOR MEVALONATE IN ACETYLATED LDL INDUCTION OF CHOLESTEROL ESTERIFICATION IN MACROPHAGES
    BERNINI, F
    DIDONI, G
    BONFADINI, G
    BELLOSTA, S
    FUMAGALLI, R
    [J]. ATHEROSCLEROSIS, 1993, 104 (1-2) : 19 - 26
  • [7] HMG-COA REDUCTASE INHIBITORS REDUCE ACETYL LDL ENDOCYTOSIS IN MOUSE PERITONEAL-MACROPHAGES
    BERNINI, F
    SCURATI, N
    BONFADINI, G
    FUMAGALLI, E
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (09) : 1352 - 1358
  • [8] ANTIATHEROSCLEROTIC ACTIVITY OF INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE IN CHOLESTEROL-FED RABBITS - A BIOCHEMICAL AND MORPHOLOGICAL EVALUATION
    BOCAN, TMA
    MAZUR, MJ
    MUELLER, SB
    BROWN, EQ
    SLISKOVIC, DR
    OBRIEN, PM
    CRESWELL, MW
    LEE, H
    UHLENDORF, PD
    ROTH, BD
    NEWTON, RS
    [J]. ATHEROSCLEROSIS, 1994, 111 (01) : 127 - 142
  • [9] The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells
    Bourcier, T
    Aikawa, M
    Libby, P
    [J]. ATHEROSCLEROSIS, 1997, 134 (1-2) : 121 - 121
  • [10] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE
    BROWN, BG
    ZHAO, XQ
    SACCO, DE
    ALBERS, JJ
    [J]. CIRCULATION, 1993, 87 (06) : 1781 - 1791